Issue #1 2019
[fusion_builder_container type=”flex” hundred_percent=”no” equal_height_columns=”no” menu_anchor=”” hide_on_mobile=”small-visibility,medium-visibility,large-visibility” class=”” id=”” background_color=”” background_image=”” background_position=”center center” background_repeat=”no-repeat” fade=”no” background_parallax=”none” parallax_speed=”0.3″ video_mp4=””[…]
Evergreening and patent cliff hangers – Article from #1 2019
The tragic 9/11 events in 2001 implied a delay in the court proceedings in Boston that dealt[…]
CRISPR/Cas9 system – Article from #1 2019
ABSTRACT The CRISPR/Cas9 discovery has emerged as a powerful technology tool to edit genomes, which allows researchers,[…]
Being equitable about equivalents – Article from #1 2019
Has Lord Neuberger in Actavis introduced “an amorphous general inventive idea” test to determine UK patent infringement[…]
Second medical use claims – Article from #1 2019
ABSTRACT Second medical use patents and their claims do not only represent highly valuable inventions for both[…]
Do rules experience culture shock – Article from #1 2019
ABSTRACT In order to stimulate product development and innovation in the pharmaceutical industry, the United States Congress[…]
The patentability of Dosage Regimes – Article from #1 2019
ABSTRACT Despite the therapeutical benefits of dosage regimes, being granted and securing patent protection for these types[…]